Allen Investment Management LLC reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 14.2% during the first quarter, according to its most recent filing with the SEC. The firm owned 37,982 shares of the company’s stock after selling 6,287 shares during the period. Allen Investment Management LLC’s holdings in Johnson & Johnson were worth $4,731,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in JNJ. Schwab Charles Investment Management Inc. boosted its position in shares of Johnson & Johnson by 1.8% in the first quarter. Schwab Charles Investment Management Inc. now owns 11,150,339 shares of the company’s stock worth $1,388,775,000 after buying an additional 201,703 shares during the period. Brown Advisory Securities LLC boosted its position in shares of Johnson & Johnson by 11.8% in the first quarter. Brown Advisory Securities LLC now owns 70,539 shares of the company’s stock worth $8,778,000 after buying an additional 7,469 shares during the period. Good Life Advisors LLC boosted its position in shares of Johnson & Johnson by 7.0% in the first quarter. Good Life Advisors LLC now owns 17,979 shares of the company’s stock worth $2,225,000 after buying an additional 1,176 shares during the period. SNS Financial Group LLC boosted its position in shares of Johnson & Johnson by 39.5% in the first quarter. SNS Financial Group LLC now owns 16,093 shares of the company’s stock worth $2,004,000 after buying an additional 4,556 shares during the period. Finally, WINTON GROUP Ltd boosted its position in shares of Johnson & Johnson by 359.2% in the first quarter. WINTON GROUP Ltd now owns 210,451 shares of the company’s stock worth $24,861,000 after buying an additional 164,619 shares during the period. 66.06% of the stock is currently owned by institutional investors and hedge funds.

Shares of Johnson & Johnson (NYSE:JNJ) traded down 0.277% during midday trading on Thursday, reaching $132.861. 541,391 shares of the company’s stock were exchanged. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $137.08. The firm has a 50-day moving average of $133.23 and a 200-day moving average of $126.11. The stock has a market capitalization of $356.60 billion, a P/E ratio of 22.481 and a beta of 0.78.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, beating analysts’ consensus estimates of $1.79 by $0.04. The business had revenue of $18.84 billion during the quarter, compared to analyst estimates of $18.94 billion. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. Johnson & Johnson’s revenue was up 1.9% compared to the same quarter last year. During the same period last year, the business earned $1.74 EPS. Analysts anticipate that Johnson & Johnson will post $7.18 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 12th. Shareholders of record on Tuesday, August 29th will be paid a dividend of $0.84 per share. The ex-dividend date is Friday, August 25th. This represents a $3.36 dividend on an annualized basis and a yield of 2.52%. Johnson & Johnson’s dividend payout ratio is currently 56.76%.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://www.watchlistnews.com/johnson-johnson-jnj-position-reduced-by-allen-investment-management-llc/1468317.html.

A number of research firms have weighed in on JNJ. Credit Suisse Group reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Friday, August 4th. Zacks Investment Research cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. Alembic Global Advisors cut shares of Johnson & Johnson from a “neutral” rating to an “underweight” rating in a research note on Friday, July 21st. Atlantic Securities cut shares of Johnson & Johnson from a “neutral” rating to an “underweight” rating and set a $113.00 target price on the stock. in a research note on Friday, July 21st. Finally, BTIG Research cut shares of Johnson & Johnson from a “neutral” rating to a “sell” rating and set a $110.00 target price on the stock. in a research note on Friday, July 21st. Three analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $133.72.

In other Johnson & Johnson news, VP Paulus Stoffels sold 102,692 shares of the firm’s stock in a transaction dated Monday, July 24th. The shares were sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the completion of the sale, the vice president now directly owns 230,342 shares in the company, valued at approximately $30,667,733.88. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Dominic J. Caruso sold 82,591 shares of the firm’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the sale, the vice president now owns 226,693 shares of the company’s stock, valued at $30,993,466.96. The disclosure for this sale can be found here. 0.19% of the stock is currently owned by company insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.